From genome sequencing to treating Crohn's disease, startups are unlocking the potential of the human microbiome.
The human microbiome is an ecosystem of trillions of microbes — some dangerous and some beneficial — living within the body. For the most part, they quietly help us digest our food, absorb nutrients, and fight off dangerous pathogens. However, when dangerous microbes, such as the bacterium C. Difficile, are allowed to multiply they can potentially wreak havoc on the digestive system causing organ failure and hospitalization.
We used the CB Insights platform to identify 24 of the most well-funded private companies targeting the microbiome and mapped them according to the 7 categories within which they operate. Ranging from developing therapeutics to treat deadly intestinal diseases to sequencing the microbial genome, these companies are reinventing modern medicine.
Since many of these companies are developing compounds to treat a variety of conditions, categories were chosen based on the mechanism of their leading therapeutic candidate.
Track all the microbiome startups in this market map and many more on our platform
Startups working in the human microbiome have the potential to upend approaches to wellness, prevention, and disease. Sign up for a free trial and look for Microbiome Startups in the Collections tab.Track Microbiome startups
Click on the image below to enlarge. This market map is not meant to be exhaustive of companies in the space.
Here are the categories in our map:
Oral Health: Companies targeting oral diseases. C3J Therapeutics, for example, is developing therapeutics to treat dental infection. C3J has developed a method of selectively targeting harmful pathogens while sparing healthy microorganisms in the mouth.
Skin Disease: Companies working to prevent and/or treat skin diseases such as acne, eczema, or dermatitis. Azitra is a research & development stage company developing a microbiome-based platform to treat a variety of skin diseases including eczema and psoriasis.
Intestinal Health: Companies working to treat diseases of the digestive system caused by an imbalance in the intestinal microbiome. Enterome is working to treat Crohn’s disease, ulcerative colitis, and irritable bowel syndrome. Second Genome is addressing inflammatory bowel disease.
Clinical Diagnostics: ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
Drug Delivery: Blue Turtle Bio is utilizing bacteria from the gut microbiome as a drug delivery platform for supplemental enzymes intended to treat enzyme-deficient disease states.
Dietary Supplements: Companies such as ISOThrive develop products to supplement or modulate the gut microbiome. ISOThrive produces prebiotics (nondigestible carbohydrates that act as food for probiotics) intended to promote digestive health.
Genomics: Companies such as uBiome are developing genomic tests meant to identify and diagnose harmful microbes in the body. uBiome’s platform, SmartGut, is a screening test used to sequence and identify the DNA of both healthy and disease-causing gut microbes.
|C3J Therapeutics||Renaissance Holding Company, Delta Dental||Oral Health|
|Naked Biome||Illumina Ventures, Undisclosed Angel Investors||Skin Disease|
|Azitra||Breakout Labs||Skin Disease|
|Xycrobe Therapeutics||Undisclosed Investors||Skin Disease|
|Symbiotic Health||Long Island Emerging Technologies Fund, Jove Equity Partners||Intestinal Health|
|Eligo Bioscience||Seventure Partners||Intestinal Health|
|Rebiotix||Quatris Fund, Michael Berman||Intestinal Health|
|Enterome||Janssen Pharmaceuticals, Nestle Health Science, Seventure Partners, Lundbeckfond Ventures||Intestinal Health|
|Vedanta Biosciences||Seventure Partners, Rock Springs Capital||Intestinal Health|
|MaaT Pharma||Biocodex||Intestinal Health|
|Second Genome||Digitalis Ventures, Pfizer Venture Investments, Roche Venture Fund, Mayo Clinic, Morgenthaler Ventures||Intestinal Health|
|Blue Turtle Bio||Indie.Bio||Drug Delivery|
|TargEDys||Pontifax, NCI, Seventure Partners||Dietary Supplements|
|MicroBiome Therapeutics||NO/LA Angel Network||Genomics|
|Evolve Biosystems||Horizons Ventures, Tate & Lyle Ventures||Genomics|
|uBiome||500 Accelerator, 8VC, Andreessen Horowitz, Slow Ventures, Y Combinator||Genomics|
|Epibiome||Silicon Valley Bank, Illumina Accelerator||Genomics|
|Realbio Technology||Bioclub, Green Pine Capital Partners, Tianheyongxin Investment||Genomics|
|Shoreline Biome||Undisclosed Investors||Genomics|
|CosmosID||Applied Value Group||Genomics|
|MicroBiome Insights||Undisclosed Investors||Genomics|
|ARTPred||Technology Foundation STW||Clinical Diagnostics|
Want more data on emerging tech trends? Check out our private company database below
This report was created with data from CB Insights’ emerging technology insights platform, which offers clarity into emerging tech and new business strategies through tools like:
- Earnings Transcripts Search Engine & Analytics to get an information edge on competitors’ and incumbents’ strategies
- Patent Analytics to see where innovation is happening next
- Company Mosaic Scores to evaluate startup health, based on our National Science Foundation-backed algorithm
- Business Relationships to quickly see a company’s competitors, partners, and more
- Market Sizing Tools to visualize market growth and spot the next big opportunity